Supercharge Your Innovation With Domain-Expert AI Agents!

Novel Anti-ctla-4 antibody polypeptide

A CTLA-4 and antibody technology, applied in the direction of antibodies, fusion polypeptides, antibody mimics/scaffolds, etc.

Active Publication Date: 2021-01-12
SHANGHAI WUXI BIOLOGIC TECH CO LTD
View PDF26 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although anti-CTLA-4 antibodies have been developed, there is still room for improvement of anti-CTLA-4 antibodies as therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel Anti-ctla-4 antibody polypeptide
  • Novel Anti-ctla-4 antibody polypeptide
  • Novel Anti-ctla-4 antibody polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0212] Example 1: Materials and Methods

[0213] 1.1 Protein preparation

[0214] 1.1.1 Preparation of human CTLA-4 and cynomolgus monkey (cynomolgus monkey) CTLA-4 ECD proteins

[0215] The human and cynomolgus monkey (cyno) CTLA-4 extracellular domain (ECD) gene and 6-histidine (6xHis) tag or Fc tag were cloned into the expression vector pcDNA3.3, and then the Expi293 expression system kit ( Invitrogen A14524) was transfected into Expi293 cells (Invitrogen A14527). Cells were cultured in Expi293 expression medium (Invitrogen A1435101) in a humidified incubator at 37°C containing 8% CO 2 and shaken at 135 rpm on an orbital shaker platform. The resulting supernatant was used for protein purification. His-tagged protein was purified with Ni-NTA column (GE Healthcare 17-5247-01), and Fc-tagged protein was purified with Protein A column (GE Healthcare 17-5438-02).

[0216] 1.1.2 Benchmark Antibodies

[0217] Reference benchmark antibody W316-BMK1

[0218] The DNA sequence o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
Login to View More

Abstract

The present disclosure provides anti-CTLA-4 antibody polypeptides, polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Description

[0001] claim of priority [0002] This patent application claims the benefit of priority of PCT application number PCT / CN2018 / 079495 filed on March 19, 2018. technical field [0003] The present invention generally relates to novel anti-human CTLA-4 antibody polypeptides. Background technique [0004] Cancer immunotherapy has become a hot area of ​​research in cancer treatment. Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) is one of the effective targets of immune checkpoints. After T cell activation, CTLA-4 is generally rapidly expressed in such T cells within 1 hour after antigen binding to TCR. CTLA-4 can inhibit T cell signaling by competing with CD28. In addition to inducible expression on activated T cells, CTLA-4 is constitutively expressed on the surface of regulatory T cells (Treg), suggesting that CTLA-4 may be required for contact-mediated inhibition and interacts with Treg to produce immunosuppressive cytokines such as Transforming growth factor beta a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13A61K39/395A61P35/00
CPCA61P35/00C07K16/2818C07K2317/22C07K2317/24C07K2317/33C07K2317/52C07K2317/569C07K2317/64C07K2317/76C07K2317/70C07K2317/732C07K2317/92C07K2317/94C07K2319/30C07K2319/00C07K2317/565C07K2317/21C07K2317/734
Inventor 陈蕴颖李竞
Owner SHANGHAI WUXI BIOLOGIC TECH CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com